

The European pharmaceutical system: strengths and weaknesses

Company perspective

Ansgar Hebborn, F. Hoffmann-La Roche AG

XIII Foresight Training Course, 23 October 2020





Eric Topol ✓
@EricTopol

A new deadly virus is sequenced in January.

Multiple vaccines are designed.

Trials of > 30,000 participants complete enrollment by October.

This represents an extraordinary biomedical research triumph.
And that's an understatement.


@EricTopol – 22.10.20 – 16:16

UNEQUAL ACCESS ACROSS THE EU – THE MAJOR WEAKNESS OF THE EU PHARMACEUTICAL SYSTEM


Are 1.000.000 deaths per year in the EU avoidable?

Largest shares of avoidable deaths in Romania, Latvia and Lithuania, lowest in France


Share of avoidable deaths in the light of current medical knowledge and technology in the EU Member States, 2015
(as % of total deaths of population aged less than 75)




Dramatic differences in the number of innovative medicines accessible to patients in EU Member States



Patients wait more than 6 times longer for access to new medicines in neighboring countries



Large economic differences between Member States with major implications for health and health systems



10 interrelated factors of why access for European patients may be delayed

Category	Potential root causes
The time prior to market authorisation	1. The speed of the regulatory process 2. Accessibility of medicines prior to marketing authorisation
The price and reimbursement process	3. Initiation of the process 4. The speed of the national timelines and adherence
The value assessment process	5. Misalignment on evidence requirement 6. Misalignment on value and price 7. The value assigned to product differentiation and choice
Health system readiness	8. Insufficient budget to implement decisions 9. Diagnosis, supporting infrastructure and relevance to patients
Delay from national to regional approval	10. Multiple layers of decision-making processes

- Rooted in the access systems and processes of EU Member States and the corresponding impact on commercial decision making
- Many interrelated factors could explain unavailability and it is not possible to untangle their impact with perfect precision

SO WHAT CAN WE DO?

The time is now!

Major EU initiatives with opportunities for improved patient access and outcomes across the EU

EU4Health

Emerged as a result to COVID-19 crisis and pushes for a stronger EU role on health issues. EU will invest financial resources to EU Member States, health organisations and NGOs with impact on healthcare staff, patients and health systems in Europe. Focus on creating reserves of medical supplies and staff and boost the cross-border health crisis response, but also on issues such as combatting the antimicrobial resistance.

Europe's Beating Cancer Plan

The current Commission's flagship initiative in health aims to improve the way we prevent, diagnose and treat cancer, in addition to the follow-up care. Special groupings across the EU institutions are evaluating opportunities for the EU to take concrete action, identifying legislation and other measures that can help prevent and fight cancer, and looking into the best ways to support research.

Pharmaceuticals Strategy

Aims to ensure equal access to safe, state-of-the-art and affordable therapies for all Europeans while taking advantage of digitalization and reducing environmental burden. The strategy will also tackle the issue of the EU's reliance on importing active pharmaceutical ingredients from third countries by incentivizing production to return to the EU, while pushing for third countries to adopt harmonized international standards on quality and safety. Linkage with Horizon Europe is anticipated.

Health Technology Assessment legislation

Assessment of the added value of new or existing health technologies – medicines, medical devices and diagnostic tools, surgical procedures, as well as measures for disease prevention, diagnosis or treatment – compared with other health technologies. Renewed interest in passing legislation post-COVID-19 by several EU Member States to gain a powerful tool in dealing with access to medicines.

EU Pharmaceutical Strategy and unequal access

Tangible progress requires a dedicated forum

- More equal access to innovative medicines across the EU is a declared key priority for the EU Pharmaceutical Strategy.
- Tangible progress requires that root causes of unequal access are identified and addressed.
- Key barriers can only be removed in multilateral engagement involving all Member States and stakeholders

ESTABLISH A FORUM FOR BETTER ACCESS TO HEALTH INNOVATION



A multi-stakeholder Forum for Better Access to Health Innovation, covering all aspects of innovation, from disease prevention, therapies, technologies, and supply chains, to improvements in care pathways and healthcare services, should be established to enhance progress towards equal access across the EU. The Forum should discuss all drivers and barriers to access innovation, including economic, budgetary, organisational, and regulatory.

The European Commission should facilitate a multi-stakeholder Forum for Better Access to Health Innovation, involving all stakeholders – from Member States and regional authorities to patients and civil society, from healthcare professionals to industry.

<https://www.euhealthcoalition.eu/recommendations/>

European solidarity between Member States beyond COVID-19

Can we finally overcome the unintended consequences of international reference pricing and parallel trade?

Countries which use international price comparisons in their negotiations with manufacturers or which are countries of reference for price purposes



efpia
European Federation of Pharmaceutical Industries and Associations

Principles for application of international reference pricing systems

International reference pricing (IRP) is a widely used element of price regulation in the vast majority of EU and EFTA countries. While IRP is inherently problematic as a means of ensuring optimal prices, these negative consequences could be at least reduced if international reference pricing systems were operated according to an established set of principles. Poorly designed pricing systems can have major negative consequences on access and affordability.

REGISTER BY 31ST OCTOBER AND SAVE £400
REGISTER BY 30TH NOVEMBER AND SAVE £200
REGISTER BY 14TH DECEMBER AND SAVE £100

SMi
LOOKING FORWARD TO INNOVATION

SMi Presents 11th Annual Conference & Exhibition on...

Parallel Trade

The opportunities and challenges ahead – beyond FMD and Brexit

CONFERENCE: 6TH - 7TH
WORKSHOPS: 8TH
FEB 2017

HOLIDAY INN KENSINGTON FORUM, LONDON, UK

CHAIRMAN:
Eric Noehrenberg, Director, Regional Market Access Lead, Latin America, Shire International GmbH

KEY SPEAKERS INCLUDE:

- Heinz Kobe, Director European Affairs, European Association of Euro-Pharmaceutical Companies
- Dr. Rick Greville, Director, Sales and Director Distribution & Supply, The Association of the British Pharmaceutical Industry
- Tomasz Dziuko, President, Dellama
- Dr. Shabnam Hanasab, Senior Consultant, IMS Health
- Dariusz Glynn, Senior Advisor, Europe Economics
- Katarzyna Kolasa, Science PhD, Warsaw Medical University
- Mike Isles, Executive Director, European Alliance for Access to Safe Medicines
- Dr. Andrew Skishorpe, Director Market Access and Managed Entry, Research Health
- Karoline Zwierzyńska, Associate, Arnold & Porter (UK) LLP
- Flemming Wagner, CEO, Abacus Medicine
- Maarten Kamphuis, Business Development Director, Fisher Pharma
- Vladimir Zah, Health Economics Consultant, ISPOR

With Brexit and the new EU Falsified Medicine Directive, what does the future hold for parallel trade? This event will discuss short term versus long term concerns of pharma manufacturers, regulators, as well as parallel traders. They will engage in an interactive debate and discuss how to keep abreast of the current trends and how to overcome all challenges. Discussion topics include:

- Parallel Trade 101 – Which factors determine the flow of pharmaceutical products in Europe?
- The European Commission's Falsified Medicines Directive – recent updates
- Panel Debate – in the spotlight: shortages
- Parallel traders panel – challenges and opportunities
- Beyond pharmaceutical products – parallel imports of medical devices
- Panel Debate – in the spotlight: Technology and new trends
- Regional and country focus – Scandinavia, UK and Eurasia

PLUS TWO INTERACTIVE HALF-DAY POST-CONFERENCE WORKSHOPS
Wednesday 8th February 2017, Holiday Inn Kensington Forum, London, UK

WORKSHOP A | 8.30 – 12.30
Managing IP and competition law issues in parallel trade
Workshop Leaders:
Ivy Ozerbay, Associate, Arnold & Porter (UK) LLP
Karoline Zwierzyńska, Associate, Arnold & Porter (UK) LLP


WORKSHOP B | 13.30 – 17.30
Parallel Trade – Management Strategies
Workshop Leader:
Janice Haigh, Practice Leader, Market Access, Quintiles

www.parallel-trade.com
Line or fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711
ACADEMIC & GROUP DISCOUNTS AVAILABLE

CPD
Continuing Professional Development
in
@SMIPHARM

Considerable increase of HTA activity in Europe

But does it need 30+ different clinical-scientific benefit assessments of the same medicine?



The changing face of biomedical innovation

A different approach to HTA is needed

- Smaller, focused RCTs, adaptive trial designs, expanded use of single-arm trials, surrogate- and intermediate endpoints
- Rare disease innovation with more limited information at the time of (initial) marketing authorization
- Increasing number of biomarker-specific therapies with co-dependencies with diagnostic technologies (“precision medicine”)
- Lifecycle approach to medicine development, substantially increased development activity after initial launch
- Faster evolution of clinical «standards of care»
- Innovation to support personalised prescribing of medicines (“clinical decision support”)

EU HTA Regulation: 3 years in the making

Proofpoint for Member States' commitment to EU collaboration?



More than 10 years of cooperation: projects, joint actions




ACHIEVEMENTS

- **Trust** between HTA bodies
- **Capacity building**
- Development of **joint tools** (e.g. EUnetHTA Core Model, POP EVIDENT databases)
- Piloting **joint work** (e.g. early dialogues, joint assessments)

LIMITATIONS

- **Low uptake of joint work** ⇒ duplication of work
- Differences in the **procedural framework** and administrative capacities of Member States
- Differences in national **methodologies**
- **No sustainability** of current cooperation model

Commission legislative proposal



Source: Sanofi




www.efpia.eu



Risk, that poor legislative compromise will add new layer of complexity to current patient access pathways.

RWE4Decisions - Towards a multi-stakeholder EU Learning Network for the use of RWE in decision making




RWE4Decisions REAL WORLD EVIDENCE

10 NOV 2020

Health Innovation – the European Health Data Space and Real-World Evidence

14.00-17.30

Virtual Conference

eu2020.de

www.rwe4decisions.com

In summary

1. Unequal access to innovative medicines across the EU is the major weakness of the EU pharmaceutical system.
2. COVID-19 experience and already existing or soon to be released EU programmes represent a major opportunity to achieve tangible progress towards more equal access across the EU.
3. Progress cannot be achieved in a vacuum. It needs a EU-level multi-stakeholder forum where root causes of unequal patient access are identified and sustainable solutions are developed, moderated by the EC.
4. Achieving rapid and meaningful progress with a EU HTA regulation that effectively reduces complexity and duration of patient access pathways will be a proofpoint for Member States' commitment to EU-level collaboration.

Doing now what patients need next